We have discovered new class of therapeutics that reduce the rate of cell growth in cancer and vascular lung diseases.

Senfina offers in vivo whole life drug discovery services for aging and age-related diseases based on a multi-feature high-throughput imaging platform using C. elegans as a model organism.

UArizona researchers have created an AI powered data-driven tool to forecast a personalized due date window for expectant mothers utilizing data from commonly worn personal devices like smart rings at various periods in gestation.

University of Arizona researchers have developed an affordable precision brace technology for carpal tunnel relief, delivering targeted compression and customized comfort to transform hand health.

Innovations in healthcare are reshaping how we diagnose gynecologic conditions like endometrial cancer, endometriosis and adenomyosis. Our groundbreaking approach focuses on non-invasive sampling coupled with advanced biomarker analysis for early detection, especially among underserved populations. By leveraging integrated technologies, we aim to revolutionize women’s health, offering timely diagnoses, improving outcomes, and ultimately saving lives. Join us in our mission to make early detection of gynecologic conditions accessible to all women, regardless of their background or resources.

Many cancer drugs suffer from severe adverse effects due to acute high exposure and inadequate distribution to tumors. This technology provides a vehicle for the preferred delivery of existing and approved drugs to tumor environments and local release of the active agent, thereby focusing exposure to tissues in need and reducing unwanted side effects.

The Atmospherica process utilizes naturally occurring, photosynthetic, shell-forming micro-algae to sequester CO2 and store it as calcium carbonate, a highly durable mineral that is stable for millions of years. It is a safe and relatively easy process that can be implemented quickly and cost effectively.

Our novel gene editing removes the immunogenicity of human Pluripotent Stem Cells upon implantation into human organs. We have chosen Type 1 Diabetes as the initial indication to demonstrate the potential of our platform.